News | Scientific evidence vs. personal experience: How do IVF patients choose treatment?
How do patients interpret medical evidence and make decisions during in vitro fertilization (IVF)? A Queen Mary University of London study published in the peer-reviewed journal Sociology of Health & Illness found markedly different attitudes and decision-making styles among IVF patients, suggesting that clinicians should provide personalized support for informed choices.
Commercialized IVF treatment: How do patients manage the information challenge?
More than 50,000 people receive fertility treatment in the UK each year, and about 70% choose additional “add-ons” in hopes of improving success. Yet these costly add-ons lack conclusive scientific evidence. Most IVF treatment is self-funded: a basic cycle costs about £3,000-£5,000 (approximately RMB 26,000-44,000), while some add-ons can bring the total to £20,000 (approximately RMB 176,000).
Private UK fertility clinics have faced criticism for marketing unproven add-ons. The BBC's Panorama reported that some IVF clinics exploited patients' vulnerability for profit. The Queen Mary University of London study, however, found that IVF patients do not passively accept marketing; they make active choices based on personal experience and differing interpretations of medical evidence.
The team conducted in-depth interviews with 51 IVF patients and partners aged 29-47 and found:
Some preferred to rely entirely on their physician's advice and avoid making the decision themselves;
Others actively researched medical evidence and were willing to accept risks to try add-ons, especially after multiple unsuccessful IVF cycles.
All participants had a basic understanding of “medical evidence,” but differed in what they considered high-quality or sufficient evidence.
Polarized decision-making styles
In the private IVF market, patients are asked to decide whether to use add-ons. Their approaches differ significantly:
Some examine medical evidence closely and use it to weigh risks and benefits. They consider clinical trial data, their own medical history and their remaining opportunities to attempt pregnancy.
Others want the physician to decide everything, preferring professional judgment to the effort of researching medical data themselves.
Regulatory involvement: Ensuring transparent information
The UK's Human Fertilisation and Embryology Authority (HFEA) is considering fines for fertility providers that misleadingly promote add-ons, while the Competition and Markets Authority (CMA) is reviewing clinics' compliance with consumer protection law.
The study offers a new policy perspective: “informed choice” requires not only transparent information but respect for different decision-making styles.
Study author: Different decision-making styles deserve respect
Lead author Dr. Manuela Perrotta, Lecturer in Technology and Organisation at Queen Mary University of London, said:
“Discussion of IVF add-ons often focuses only on how private clinics ‘deceive’ patients into buying ineffective treatments, but that is only part of the issue. Our study shows that patients do not decide blindly; they actively make complex decisions based on their experiences and how they assess risk.”
Dr. Perrotta further emphasized that “informed choice” should mean more than providing scientific data; patients must be able to understand the information.
“Some patients want detailed medical explanations and to decide for themselves, while others prefer to trust their physician's professional judgment. Both choices should be respected.”
IVF decisions are reasoned tradeoffs, not blind impulses
Co-author Dr. Josie Hamper, a postdoctoral researcher at Queen Mary University of London, said:
“We challenge the common misconception that desperate IVF patients readily believe claims for expensive treatments. Instead, most actively assess risk and decide only after considering personal experience, medical evidence and financial cost.”
“Willingness to pay for private IVF and choose certain add-ons does not mean patients lack scientific literacy or blindly trust marketing. These are personalized decisions within their own fertility journeys.”
Conclusion
As the global fertility treatment market grows, balancing commercialization with medical evidence is an important challenge for regulators.
The study highlights the complexity of IVF decision-making. Clinicians and healthcare organizations should provide personalized support and clear medical information so patients can make the best choice for them.
News | Scientific evidence vs. personal experience: How do IVF patients choose treatment?
News | Scientific evidence vs. personal experience: How do IVF patients choose treatment?
How do patients interpret medical evidence and make decisions during in vitro fertilization (IVF)? A Queen Mary University of London study published in the peer-reviewed journal Sociology of Health & Illness found markedly different attitudes and decision-making styles among IVF patients, suggesting that clinicians should provide personalized support for informed choices.
Commercialized IVF treatment: How do patients manage the information challenge?
More than 50,000 people receive fertility treatment in the UK each year, and about 70% choose additional “add-ons” in hopes of improving success. Yet these costly add-ons lack conclusive scientific evidence. Most IVF treatment is self-funded: a basic cycle costs about £3,000-£5,000 (approximately RMB 26,000-44,000), while some add-ons can bring the total to £20,000 (approximately RMB 176,000).
Private UK fertility clinics have faced criticism for marketing unproven add-ons. The BBC's Panorama reported that some IVF clinics exploited patients' vulnerability for profit. The Queen Mary University of London study, however, found that IVF patients do not passively accept marketing; they make active choices based on personal experience and differing interpretations of medical evidence.
Findings: Patients understand “medical evidence” differently
The team conducted in-depth interviews with 51 IVF patients and partners aged 29-47 and found:
Some preferred to rely entirely on their physician's advice and avoid making the decision themselves;
Others actively researched medical evidence and were willing to accept risks to try add-ons, especially after multiple unsuccessful IVF cycles.
All participants had a basic understanding of “medical evidence,” but differed in what they considered high-quality or sufficient evidence.
Polarized decision-making styles
In the private IVF market, patients are asked to decide whether to use add-ons. Their approaches differ significantly:
Some examine medical evidence closely and use it to weigh risks and benefits. They consider clinical trial data, their own medical history and their remaining opportunities to attempt pregnancy.
Others want the physician to decide everything, preferring professional judgment to the effort of researching medical data themselves.
Regulatory involvement: Ensuring transparent information
The UK's Human Fertilisation and Embryology Authority (HFEA) is considering fines for fertility providers that misleadingly promote add-ons, while the Competition and Markets Authority (CMA) is reviewing clinics' compliance with consumer protection law.
The study offers a new policy perspective: “informed choice” requires not only transparent information but respect for different decision-making styles.
Study author: Different decision-making styles deserve respect
Lead author Dr. Manuela Perrotta, Lecturer in Technology and Organisation at Queen Mary University of London, said:
“Discussion of IVF add-ons often focuses only on how private clinics ‘deceive’ patients into buying ineffective treatments, but that is only part of the issue. Our study shows that patients do not decide blindly; they actively make complex decisions based on their experiences and how they assess risk.”
Dr. Perrotta further emphasized that “informed choice” should mean more than providing scientific data; patients must be able to understand the information.
“Some patients want detailed medical explanations and to decide for themselves, while others prefer to trust their physician's professional judgment. Both choices should be respected.”
IVF decisions are reasoned tradeoffs, not blind impulses
Co-author Dr. Josie Hamper, a postdoctoral researcher at Queen Mary University of London, said:
“We challenge the common misconception that desperate IVF patients readily believe claims for expensive treatments. Instead, most actively assess risk and decide only after considering personal experience, medical evidence and financial cost.”
“Willingness to pay for private IVF and choose certain add-ons does not mean patients lack scientific literacy or blindly trust marketing. These are personalized decisions within their own fertility journeys.”
Conclusion
As the global fertility treatment market grows, balancing commercialization with medical evidence is an important challenge for regulators.
The study highlights the complexity of IVF decision-making. Clinicians and healthcare organizations should provide personalized support and clear medical information so patients can make the best choice for them.
Story source:
Collected online